Consequently, it is of interest to study the prevalence of and susceptibility to VEGF and other growth factors in the GCs of different lesions, as giant cell tumours of the bone have been shown to be sensitive to antiangiogenetic tyrosine kinase inhibitor treatment combined with Denosumab [182]. The gene discussed is VEGFA; the disease is giant cell tumor.